Meanwhile, although there is progress in the development of new TB diagnostics, drugs and vaccines, this is constrained by the overall level of R&D investment, which at US$ 0.9 billion in 2019 falls far short of the global target of US$ 2 billion The report notes a fall in global spending on TB diagnostic, treatment and prevention services, from US$ 5.8 billion to US$ 5.3 billion, which is less than half of the global target for fully funding the TB response of US$ 13 billion annually by 2022. The biggest international donor is the Global Fund to Fight AIDS, Tuberculosis and Malaria.
The largest bilateral donor is the Government of the United States of America. Of the total funding available in 2020, 81% came from domestic sources, with the BRICS countries (Brazil, Russian Federation, India,Ĭhina and South Africa) accounting for 65% of total domestic funding. Global investment for TB fallsįunding in the low- and middle-income countries (LMICs) that account for 98% of reported TB cases remains a challenge. To 150 000 in 2020, equivalent to only about 1 in 3 of those in need. In addition, the number of people treated for drug-resistant TB fell by 15%, from 177 000 in 2019 Some 2.8 million people accessed this in 2020, a 21% reduction since 2019. There was also a reduction in provision of TB preventive treatment. These and 12 other countries accounted for 93% of the total global drop in notifications. The countries that contributed most to the global reduction in TB notifications between 20 were India (41%), Indonesia (14%), the Philippines (12%) and China (8%). This figure is up from 2.9 million in 2019. WHO estimates that some 4.1 million people currently suffer from TB but have not been diagnosed with the disease or have not officially reported to national authorities. The number of people newly diagnosed with TB and those reported to national governments fell from 7.1 million in 2019 to WHO modelling projections suggest the number of peopleĭeveloping TB and dying from the disease could be much higher in 20.Ĭhallenges with providing and accessing essential TB services have meant that many people with TB were not diagnosed in 2020.
The increase in the number of TB deaths occurred mainly in the 30 countries with the highest burden of TB. TB services are among many others disrupted by the COVID-19 pandemic in 2020, but the impact on TB has been particularly severe.įor example, approximately, 1.5 million people died from TB in 2020 (including 214 000 among HIV positive people). News that must serve as a global wake-up call to the urgent need for investments and innovation to close the gaps in diagnosis, treatment and care for the millions of people affected by this ancient but preventable and treatable disease.”
“This report confirms our fears that the disruption of essential health services due to the pandemic could start to unravel years of progress against tuberculosis,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
The second is that people have struggled to seek care in the context of lockdowns. In many countries, human, financial and other resources have been reallocated from tackling TB to the COVID-19 response, limiting the availability of essential services. The first challenge is disruption in access to TB services and a reduction in resources. In 2020, more people died from TB, with far fewer people being diagnosed and treated or provided with TB preventive treatment compared with 2019, and overall spending on essential TB services falling. The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and for the first time in over a decade, TB deaths have increased, according to the World Health Organization’s 2021 Global TB report.
0 kommentar(er)
